Paul Fields

Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma

Martin Hutchings, N. George Mikhaeel, Paul Fields et al. · Annals of Oncology · 2005 · 328 citations · Full text

Medicine, Oncology, Chemotherapy +9

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

Andrew Davies, Thomas Cummin, Sharon Barrans et al. · The Lancet Oncology · 2019 · 272 citations · Full text

Medicine, Hematology, Oncology +15

A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome

Emma Benton, Siobhan Crichton, R. Talpur et al. · European Journal of Cancer · 2013 · 158 citations

Medicine, Dermatology, Oncology +13

Diagnosis and Subtyping of <i>De Novo</i> and Relapsed Mediastinal Lymphomas by Endobronchial Ultrasound Needle Aspiration

Mufaddal Moonim, Ronan Breen, Paul Fields et al. · American Journal of Respiratory and Critical Care Medicine · 2013 · 93 citations · Full text

Medicine, Internal Medicine, Oncology +15

Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study

Mehdi Hamadani, Graham P. Collins, Paolo F. Caimi et al. · The Lancet Haematology · 2021 · 86 citations · Full text

Medicine, Immunology, Oncology +17